2020
Cystatin C and Muscle Mass in Patients With Heart Failure
Ivey-Miranda JB, Inker LA, Griffin M, Rao V, Maulion C, Turner JM, Wilson FP, Tang WHW, Levey AS, Testani JM. Cystatin C and Muscle Mass in Patients With Heart Failure. Journal Of Cardiac Failure 2020, 27: 48-56. PMID: 32750487, PMCID: PMC8672303, DOI: 10.1016/j.cardfail.2020.07.013.Peer-Reviewed Original ResearchConceptsHeart failureCreatinine clearanceMuscle massCystatin CHigher muscle massAssociation of eGFRcysGlomerular filtration rateLow muscle massCystatin C levelsAccurate GFR estimationMultivariable analysisFiltration rateEGFRcysEGFRcrBody compositionGFR estimationPatientsCreatinineC levelsClearanceMortalityAssociation
2018
Barriers to Advance Care Planning in End-Stage Renal Disease: Who is to Blame, and What Can be Done?
Kelley AT, Turner J, Doolittle B. Barriers to Advance Care Planning in End-Stage Renal Disease: Who is to Blame, and What Can be Done? The New Bioethics 2018, 24: 150-157. PMID: 29513084, DOI: 10.1080/20502877.2018.1438772.Peer-Reviewed Case Reports and Technical NotesConceptsAdvance care planningCare planningEnd-stage renal diseaseChronic kidney diseaseCourse of diseaseRenal diseaseKidney diseaseIntensive treatmentAdvance carePatient valuesCognitive declinePatientsSignificant mortalityClinical literatureDecision-making capacityDaily practiceDiseaseYears of supportPhysiciansConvincing evidenceMore trainingMorbidityHospitalClinicMortality
2017
Blood pressure targets for hemodialysis patients
Turner JM, Peixoto AJ. Blood pressure targets for hemodialysis patients. Kidney International 2017, 92: 816-823. PMID: 28938954, DOI: 10.1016/j.kint.2017.01.038.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDialysis unit blood pressureHemodialysis patientsBlood pressureBP targetsBlood pressure targetsLarge observational studiesBenefit-risk balanceBP reductionPressure targetsBP managementTreatment strategiesObservational studyCurrent evidenceDialysis providersGeneral populationClinical practicePatientsHypertensionNephrologistsPopulationTargetMortalityTrials
2016
We Avoid RAAS Inhibitors in PD Patients with Residual Renal Function
Turner JM. We Avoid RAAS Inhibitors in PD Patients with Residual Renal Function. Seminars In Dialysis 2016, 29: 265-267. PMID: 27061273, DOI: 10.1111/sdi.12488.Commentaries, Editorials and LettersConceptsResidual renal functionPeritoneal dialysisRAAS inhibitorsRenal functionAngiotensin receptor blockersGlomerular filtration rateRAAS blockadeAldosterone systemReceptor blockersNephrotoxic agentsPD patientsPD populationFiltration rateModality failureUltrafiltration failureEnzyme inhibitorsPatientsPeritoneal membraneMorphologic changesInhibitorsMortalityCliniciansAnuriaAngiotensinFailure